An observational study in Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia and Myelodysplasia, sponsored by Beth Israel Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-17.
Sponsored by Beth Israel Medical Center · Observational
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia.
To develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one another.
To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated destruction of platelets.
Patient to be registered at the Haematology-Oncology department Mount Sinai Roosevelt Hospital.
Inclusion criteria are as follows:
All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by response to IVIG, glucocorticoids, or WinRho and exclusion of all other possible causes of thrombocytopenia Confirmed aplastic anemia [as assessed through bone marrow trephine biopsy]. Chemotherapy-induced thrombocytopenia assessed at time of predicted nadir.
1,317 studies on the registry are indexed under Preleukemia; 57 are open to participants now.
This study's enrollment of 50 is below the median of 114 across 116 observational studies indexed under Preleukemia.
Browse Preleukemia studies →Beth Israel Medical Center is the lead sponsor of 50 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population would consist of adult female and male subjects of all ethnic persuasions in good general health apart from thrombocytopenia, bone marrow aplasia, myelodysplasia, or active malignancy requiring therapy. Vulnerable strata of the hospital population will not be recruited into the study.
Exclusion Criteria:
The study shall be a single institution prospective cohort study. Comparison will be made among individuals with known ITP . Those with known hypo-proliferative forms of thrombocytopenia \[aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia, and a control population.
Other: Immune Thrombocytopenics
The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia \[aplastic anaemia, chemotherapy--induced thrombocytopenia, and myelodysplastic thrombocytopenia\], and a control population.
Other: Hypo-proliferative thrombocytopenics
comprised of healthy individuals with normal platelet counts, to confirm normal values for MPC and MPM
Other: Control Population
Full blood count with extended platelet parameters
Also known as: MPC (g/dl), MPM (pg)
Full blood count with extended platelet parameters
Also known as: MPC (g/dl), MPM (pg)
Full blood count with extended platelet parameters
Also known as: MPC (g/dl), MPM (pg)
Increased platelet density
Time frame: 12 months
mean platelet mass
Time frame: 12 months
Platelet mass distribution width
Time frame: 12 Months
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beth Israel Medical Center